the big pictureAducanumab is not great, but it would be a step in the right direction. The question likely weighing on the FDA is the cost-benefit. Hopefully they are considering the opportunity costs associated with next-gen product development and the impacts of their decision on the industry as a whole.
In a previous post, several options were presented- approval, rejection, or restricted approval. I worry the latter might also restrict the potential benefits associated with early intervention based on biomarkers.
As an APOE-4 variant carrier (just found that out last week thanks to 23andme), I'd be okay with approval. Thankfully, I've got a couple decades between now and possible onset.
As a PMN shareholder, I'd definitely be okay with approval!
Enjoy your weekend. Monday could be interesting... 8-)